Prof.Dr.Engin
K E L K İ T L İ
POMALİDOMİD
- Pomalidomid
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. (J Clin Oncol. 2009;27(30):5008.)
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). (Leukemia. 2010 Nov;24(11):1934-9)
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. (Blood. 2011;118(11):2970.)
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.( Blood. 2014 Mar;123(12):1826-32.)
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (Blood. 2013;121(11):1968.)
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial (Lancet Oncol. 2013;14(11):1055.)
- Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. (Blood. 2013 Oct;122(16):2799-806.)